Advanced search
Publication Cover
Expert Review of Anticancer Therapy Volume 20, 2020 - Issue 5
Submit an article Journal homepage
517
Views
6
CrossRef citations to date
0
Altmetric
Review

EGFR mutation-positive NSCLC: factors to consider when deciding first-line therapy

Pauline HuloThoracic Oncology Unit, Nantes University Hospital, Nantes, France;INSERM, CRCINA, Nantes, FranceView further author information
,
Dahna CoupezThoracic Oncology Unit, Nantes University Hospital, Nantes, FranceView further author information
,
Marc G DenisDepartment of Biochemistry and Molecular Biology, Nantes University Hospital, Nantes, France;University of Nantes, FranceView further author information
&
Jaafar BennounaThoracic Oncology Unit, Nantes University Hospital, Nantes, France;INSERM, CRCINA, Nantes, France;University of Nantes, FranceCorrespondence[email protected]
View further author information
Pages 365-372 | Received 17 Dec 2019, Accepted 15 Apr 2020, Published online: 26 Apr 2020

Citations (6)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Marc G Denis & Jaafar Bennouna. (2020) Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic EGFR-Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments. Cancer Management and Research 12, pages 12593-12602.
Read now

Articles from other publishers (5)

Xueyun Tan, Yuan Li, Sufei Wang, Hui Xia, Rui Meng, Juanjuan Xu, Yanran Duan, Yan Li, Guanghai Yang, Yanling Ma & Yang Jin. (2022) Predicting EGFR mutation, ALK rearrangement, and uncommon EGFR mutation in NSCLC patients by driverless artificial intelligence: a cohort study. Respiratory Research 23:1.
Crossref
Man Qiao, Dongsheng Li, Yuan He, Cen Zhang, Hang Chi, Xiaoqiu Li, QingMing Cui, ShaoYing Li, Ying Jiao & Yuan Wei. (2022) Detection and Significance of Cell-Free DNA Mutation in Pleural Effusion in Patients with Advanced NSCLC. Emergency Medicine International 2022, pages 1-5.
Crossref
David S. Schrump & Chuong D. Hoang. (2021) Commentary: Keeping the target painted for precision cancer therapy. The Journal of Thoracic and Cardiovascular Surgery 162:2, pages 475-476.
Crossref
Youxi Han, Ronghui Ma, Guolei Cao, Hao Liu, Lili He, Le Tang, Hong Li & Qin Luo. (2021) Combined Treatment of Cinobufotalin and Gefitinib Exhibits Potent Efficacy against Lung Cancer. Evidence-Based Complementary and Alternative Medicine 2021, pages 1-9.
Crossref
Paul Dent. 2021. YY1 in the Control of the Pathogenesis and Drug Resistance of Cancer. YY1 in the Control of the Pathogenesis and Drug Resistance of Cancer 243 249 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.